Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jul 29, 2020

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
- Photos 3
Jul 14, 2020

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
Jul 2, 2020

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Jun 30, 2020

Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders
Jun 29, 2020

Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index
Jun 22, 2020

Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jun 19, 2020

FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration

* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
Jun 17, 2020

Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock
Jun 16, 2020

Provention Bio Announces Proposed Public Offering of Common Stock
Jun 15, 2020

Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients

-One Course of Teplizumab Now Shown to Delay Insulin-Dependent T1D by a Median of Approximately Three Years Compared to Placebo-

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.